Kintegral Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Kintegral Advisory’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.04M	Sell	116,111 -5,148	-4%	-$300K	0.67%	34
2025 Q4	$6.54M	Sell	121,259 -3,319	-3%	-$160K	0.55%	46
2025 Q3	$5.62M	Sell	124,578 -557	-0.4%	-$26K	0.48%	53
2025 Q2	$5.79M	Sell	125,135 -188	-0.2%	-$9.23K	0.53%	52
2025 Q1	$7.64M	Sell	125,323 -422	-0.3%	-$24.6K	0.77%	29
2024 Q4	$7.11M	Sell	125,745 -5,858	-4%	-$327K	0.67%	35
2024 Q3	$6.81M	Sell	131,603 -1,724	-1%	-$80.9K	0.62%	40
2024 Q2	$5.54M	Buy	133,327 +55,204	+71%	+$2.47M	0.53%	48
2024 Q1	$4.24M	Sell	78,123 -244	-0.3%	-$12.4K	0.42%	67
2023 Q4	$4.02M	Sell	78,367 -499	-0.6%	-$26.2K	0.45%	59
2023 Q3	$4.58M	Sell	78,866 -47	-0.1%	-$2.88K	0.57%	45
2023 Q2	$5.05M	Hold	78,913	–	–	0.6%	41
2023 Q1	$5.47M	Sell	78,913 -4,240	-5%	-$299K	0.71%	37
2022 Q4	$5.98M	Buy	83,153 +17,254	+26%	+$1.3M	0.79%	33
2022 Q3	$4.68M	Hold	65,899	–	–	0.65%	32
2022 Q2	$5.11M	Buy	65,899 +1,395	+2%	+$106K	0.66%	33
2022 Q1	$4.75M	Buy	64,504 +1,443	+2%	+$96.9K	0.52%	42
2021 Q4	$3.93M	Hold	63,061	–	–	0.41%	57
2021 Q3	$3.76M	Hold	63,061	–	–	0.44%	59
2021 Q2	$4.21M	Hold	63,061	–	–	0.5%	52
2021 Q1	$4.01M	Hold	63,061	–	–	0.52%	48
2020 Q4	$3.94M	Hold	63,061	–	–	0.54%	46
2020 Q3	$3.8M	Sell	63,061 -2,030	-3%	-$122K	0.58%	42
2020 Q2	$3.83M	Hold	65,091	–	–	0.62%	38
2020 Q1	$3.63M	Buy	65,091 +7,284	+13%	+$445K	0.71%	35
2019 Q4	$3.71M	Buy	57,807 +17,299	+43%	+$991K	0.67%	36
2019 Q3	$2.05M	Hold	40,508	–	–	0.41%	73
2019 Q2	$1.84M	Hold	40,508	–	–	0.37%	79
2019 Q1	$1.93M	Buy	40,508 +20,814	+106%	+$1.04M	0.41%	72
2018 Q4	$1.02M	Buy	+19,694	New	+$1.06M	0.3%	83

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kintegral Advisory's BMY Position: Q1 2026 in Review

Kintegral Advisory reduced its Bristol-Myers Squibb (BMY) stake by 4.2% in Q1 2026, selling an estimated $300K and leaving 116,111 shares worth $7.04M. The position accounts for 0.67% of the portfolio, ranked #34.

Kintegral Advisory first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $7.64M in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Kintegral Advisory held 116,111 shares of Bristol-Myers Squibb worth $7.04M as of Q1 2026.
Kintegral Advisory sold 5,148 Bristol-Myers Squibb shares in Q1 2026, an estimated $300K.
Bristol-Myers Squibb made up 0.67% of Kintegral Advisory's portfolio in Q1 2026, its #34 holding.
Kintegral Advisory first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
Kintegral Advisory's Bristol-Myers Squibb position peaked at $7.64M in Q1 2025.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Kintegral Advisory's 13F filing for Q1 2026, filed 14 May 2026.